OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX – Get Free Report) in a report issued on Tuesday. The brokerage set a “sell” rating on the stock.

OncoCyte Stock Down 2.0 %

Shares of OCX stock opened at $3.51 on Tuesday. OncoCyte has a 52 week low of $3.48 and a 52 week high of $22.00. The firm’s 50-day simple moving average is $7.35 and its two-hundred day simple moving average is $5.57.

Get OncoCyte alerts:

OncoCyte (NASDAQ:OCX – Get Free Report) last posted its quarterly earnings results on Thursday, May 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.40) by $1.60. The business had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.50 million. Research analysts expect that OncoCyte will post -4.2 earnings per share for the current year.

Institutional Trading of OncoCyte

Several hedge funds and other institutional investors have recently modified their holdings of OCX. Cubist Systematic Strategies LLC purchased a new position in OncoCyte during the second quarter valued at approximately $25,000. Raymond James Financial Services Advisors Inc. purchased a new position in OncoCyte during the first quarter valued at approximately $25,000. DCF Advisers LLC grew its stake in OncoCyte by 107.0% during the first quarter. DCF Advisers LLC now owns 25,149 shares of the company’s stock valued at $37,000 after acquiring an additional 13,000 shares in the last quarter. Balyasny Asset Management LLC grew its stake in OncoCyte by 389.9% during the third quarter. Balyasny Asset Management LLC now owns 52,887 shares of the company’s stock valued at $39,000 after acquiring an additional 42,091 shares in the last quarter. Finally, LPL Financial LLC grew its stake in OncoCyte by 58.1% during the second quarter. LPL Financial LLC now owns 108,816 shares of the company’s stock valued at $98,000 after acquiring an additional 40,000 shares in the last quarter. Institutional investors own 69.93% of the company’s stock.

OncoCyte Company Profile

(Get Free Report)

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay.

Recommended Stories

• Five stocks we like better than OncoCyte
• What Are Utility Stocks? An Overview of the Utilities Sector
• 3 Best Renewable Energy Stocks as Summer Heat Builds
• How to Invest in Fertilizer
• Kinder Morgan Shines With Dividend Yield, Cash Flow, Buybacks
• Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
• 3 Stocks to Buy No Matter Which Way Inflation Moves

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.